Who should be treated for nontuberculous mycobacterial pulmonary disease?

Respir Investig. 2023 Jul;61(4):387-388. doi: 10.1016/j.resinv.2023.03.002. Epub 2023 Apr 19.

Author

Yutaka Ito¹

Affiliation

¹ Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan. Electronic address: yutaka@med.nagoya-cu.ac.jp.

PMID: 37079944
DOI: 10.1016/j.resinv.2023.03.002

No abstract available

Keywords: Guideline; Nontuberculous mycobacteria; Patient-reported outcome; Sputum conversion; Treatment.

Publication types

Editorial

MeSH terms

Humans
Lung Diseases* / therapy
Mycobacterium Infections, Nontuberculous* / drug therapy
Mycobacterium Infections, Nontuberculous* / microbiology